Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | May 14, 2026 | May 18, 2026 |
| IMMUNE DESIGN CORP.IMDZ · Entity 158527 | Director · President and CEO | April 02, 2019 | April 04, 2019 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | June 14, 2023 | June 17, 2023 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date May 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,323 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 8,741 · Balance 28,323 F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
1 source rowRow 1 · 2019-04-02 · Disposition to issuer · Disposed 35,576 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-02 · Disposition to issuer · Disposed 121,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-02 · Disposition to issuer · Disposed 195,289 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-02 · Disposition to issuer · Disposed 67,277 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-02 · Disposition to issuer · Disposed 61,161 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.23 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-02 · Disposition to issuer · Disposed 244,648 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-04-02 · Disposition to issuer · Disposed 175,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-04-02 · Disposition to issuer · Disposed 216,500 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.40 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-04-02 · Disposition to issuer · Disposed 263,009 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
| Stock Option (Rt to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-04-02 · Disposition to issuer · Disposed 293,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3: Not Applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated February 20, 2019, by and among the Immune Design Corp. (the "Issuer"), Merck Sharp & Dohme Corp., a New Jersey corporation ("Parent") and Cascade Merger Sub Inc., a Delaware corporation ("Purchaser"), on April 2, 2019, Purchaser merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. In connection with the Merger, the Issuer's common stock were cancelled and converted into the right to receive $5.85 in cash per share, less any required withholding, subject to the terms and conditions of the Merger Agreement ("Merger Consideration").
F2: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these unvested restricted stock units vested automatically in accordance with their terms and were cancelled and automatically converted into the right to receive the Merger Consideration in respect of each share of Issuer common stock underlying such awards.
F3: Not Applicable.
F4: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share.
STANDARD BIOTOOLS INC.
Report date June 14, 2023 · Filed June 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,844 |
Reported balance
After 2023-06-14 transaction · row 1
1 source rowRow 1 · 2023-06-14 · Grant · Acquired 26,376 · Balance 126,844 F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2033-06-14 | Direct | 35,380 |
Reported balance
After 2023-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-14 · Grant · Acquired 35,380 · Balance 35,380 F2: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.
F2: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,856 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 6,856 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Trust | 5,625 |
Reported balance
Holding disclosure · report date 2026-06-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,625 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 16, 2026 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 11,389 | $0.00 Strike: $49.56 | $0.00 |
DisclosureSEC source: 0001606244-26-000004 · wk-form4_1781641275.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,389 Underlying: Common Stock · 11,389 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 20:21 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001606244-26-000004 · wk-form4_1781641275.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,856 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control. Read SEC document |
| May 14, 2026 Filed May 18, 2026 20:15 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 8,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001606244-26-000002 · form4-05182026_040514.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,323 F1 · kind: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,372 | $0.00 Strike: $34.46 | $0.00 |
DisclosureSEC source: 0001606244-25-000003 · wk-form4_1750111529.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,372 Underlying: Common Stock · 15,372 shares Expires 2035-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 22:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001606244-25-000003 · wk-form4_1750111529.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,591 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 12, 2026 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:37 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 19,582 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009804 · form4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,582 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. 9,791 of the RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders; 9,791 of the RSUs vest on May 15, 2026, in each case subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000122 · wk-form4_1733865288.xml · derivative · entry 4 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F4 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. F3 · ownership.nature: Shares are held directly by a trust for the sole benefit of the Reporting Person. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000122 · wk-form4_1733865288.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F4 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000122 · wk-form4_1733865288.xml · nonDerivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 5,625 F3 · ownership.nature: Shares are held directly by a trust for the sole benefit of the Reporting Person. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:14 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000122 · wk-form4_1733865288.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,550 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F2 · balance_after: As previously disclosed in Reporting Person's Form 4 filed on June 10, 2024, this represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 7,250 | $0.00 Strike: $72.51 | $0.00 |
DisclosureSEC source: 0001649094-24-000009 · wk-form4_1718049932.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,250 Underlying: Common Stock · 7,250 shares Expires 2034-06-05 F3 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:05 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 1,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001649094-24-000009 · wk-form4_1718049932.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,050 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 6, 2025 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · derivative · entry 8 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F7 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. F5 · ownership.nature: Options are held directly by a trust for the sole benefit of the Reporting Person. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · derivative · entry 7 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F7 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · derivative · entry 6 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F6 · derivative.exercise_date: The shares of Common Stock subject to the option vested fully on June 1, 2023. F5 · ownership.nature: Options are held directly by a trust for the sole benefit of the Reporting Person. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · derivative · entry 5 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F6 · derivative.exercise_date: The shares of Common Stock subject to the option vested fully on June 1, 2023. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · derivative · entry 4 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-10-26 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F4 · derivative.exercise_date: Option vests over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. F5 · ownership.nature: Options are held directly by a trust for the sole benefit of the Reporting Person. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2031-10-26 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F4 · derivative.exercise_date: Option vests over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · nonDerivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trust Disclosed balance after: 3,125 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F3 · ownership.nature: Shares are held directly by a trust for the sole benefit of the Reporting Person. Read SEC document |
| November 09, 2023 Filed Nov 9, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GiftCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-054846 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 F1 · shares: The reported transactions involve the Reporting Person's transfer of certain securities to a trust for the sole benefit of the Reporting Person. F2 · balance_after: As previously disclosed in Reporting Person's Form 4 filed on June 15, 2023, this represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:44 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 35,380 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001162194-23-000044 · wk-form4_1686962679.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,380 Underlying: Common Stock · 35,380 shares Expires 2033-06-14 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 00:44 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 26,376 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000044 · wk-form4_1686962679.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,844 F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $53.08 | $0.00 |
DisclosureSEC source: 0001209191-23-037497 · doc4.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-12 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:51 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-037497 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,625 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 13, 2024 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 42,571 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001162194-22-000077 · wf-form4_165550349980323.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,571 Underlying: Common Stock · 42,571 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 15, 2022. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:05 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 30,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-22-000077 · wf-form4_165550349980323.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,468 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of June 15, 2023 and one day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 18,750 | $0.00 Strike: $22.70 | $0.00 |
DisclosureSEC source: 0001209191-22-034069 · doc4.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2032-05-31 F2 · derivative.exercise_date: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:33 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 3,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034069 · doc4.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,125 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 1, 2023 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Read SEC document |
| October 27, 2021 Filed Oct 29, 2021 22:12 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $22.02 | $0.00 |
DisclosureSEC source: 0001209191-21-062120 · doc4.xml · derivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-10-26 F1 · derivative.exercise_date: Option shall vest over 36 months, 1/3 of which will vest on October 27, 2022 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:32 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 15,402 | $0.00 Strike: $5.56 | $0.00 |
DisclosureSEC source: 0001162194-21-000062 · wf-form4_162215106853926.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,402 Underlying: Common Stock · 15,402 shares Expires 2031-05-25 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on June 25, 2021. Read SEC document |
| May 25, 2021 Filed May 27, 2021 21:32 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 10,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000062 · wf-form4_162215106853926.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,554 F1 · shares: The Restricted Stock Units vest in full on the earlier to occur of May 25, 2022 and one day prior to the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:10 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000017 · wf-form4_161670659416602.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock. F2 · derivative.exercise_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units vesting as to 25% of the shares underlying the Restricted Stock Units on each anniversary date after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. F2 · derivative.expiration_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units vesting as to 25% of the shares underlying the Restricted Stock Units on each anniversary date after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:10 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-21-000017 · wf-form4_161670659416602.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:26 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 16,614 | $0.40 | $6,715.38 |
DisclosureSEC source: 0000950138-21-000224 · edgar.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.40 to $0.41, inclusive. Mr. Paya will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:00 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 20,993 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001162194-20-000085 · wf-form4_159311519874436.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,993 Underlying: Common Stock · 20,993 shares Expires 2030-06-23 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 23, 2020. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 20:00 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 13,369 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-20-000085 · wf-form4_159311519874436.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,712 F1 · shares: The Restricted Stock Units vest in full on the earlier to occur of June 23, 2021 and one day prior to the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:32 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 14,735 | $2.96 | $43,615.60 |
DisclosureSEC source: 0000950138-20-000261 · edgar.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,614 Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 21:25 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-20-000031 · wf-form4_158517151303374.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of FLDM common stock. F2 · derivative.exercise_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units vesting as to 25% of the shares underlying the Restricted Stock Units on each anniversary date after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. F2 · derivative.expiration_date: On March 23, 2017, the Reporting Person was granted 10,000 Restricted Stock Units vesting as to 25% of the shares underlying the Restricted Stock Units on each anniversary date after the date of grant on the same day of the month as the date of grant, subject to continued service as a director. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 21:25 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-20-000031 · wf-form4_158517151303374.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:40 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantStock Option (Right to Buy) · Derivative | 6,796 | $0.00 Strike: $13.41 | $0.00 |
DisclosureSEC source: 0001162194-19-000052 · wf-form4_155975643501913.xml · derivative · entry 2 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,796 Underlying: Common Stock · 6,796 shares Expires 2029-06-03 F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly installments beginning on July 3, 2019. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 17:40 UTC | STANDARD BIOTOOLS INC. FLDM · Entity 6116 | GrantCommon Stock | 3,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-19-000052 · wf-form4_155975643501913.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,843 F1 · shares: Represents Restricted Stock Units that vest in full on the earlier to occur of June 3, 2020 and one day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 22, 2019 Filed May 24, 2019 20:22 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 31,349 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000325 · edgar.xml · nonDerivative · entry 1 Paya Carlos V · CIK 0001606244 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,349 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 293,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 10 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 263,009 | Not disclosed Strike: $4.40 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 9 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 263,009 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 216,500 | Not disclosed Strike: $4.05 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 8 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 216,500 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 175,000 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 7 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 244,648 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 6 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 244,648 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 61,161 | Not disclosed Strike: $1.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 5 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 61,161 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 67,277 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 4 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,277 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
| April 02, 2019 Filed Apr 4, 2019 17:14 UTC | IMMUNE DESIGN CORP. IMDZ · Entity 158527 | Disposition to issuerStock Option (Rt to Buy) · Derivative | 195,289 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001209191-19-023685 · doc4.xml · derivative · entry 3 Paya Carlos V · CIK 0001606244 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 195,289 shares Expires not disclosed F4 · price: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the effective time of the Merger, each of these stock options accelerated and became fully vested and converted into the right to receive cash in the amount equal to the product of (i) the total number of Shares subject to the such stock option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (x) the Merger Consideration over (y) the exercise price payable per share. F3 · derivative.expiration_date: Not Applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.